The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma

A. Maki, H. Diwakaran, B. Redman, S. Al-Asfar, George Pettit, R. M. Mohammed, A. Al-Katib

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The effects of dolastatin 10 (Dol10) and dolastatin 15 (Dol15) alone, and after treatment with bryostatin 1 (Bryo1), on human diffuse large cell lymphoma cell line (WSU-DLCL2) were studied. At a concentration of 1.0 ng/ml Dol10 and Dol15 showed significant growth inhibition (p < 0.05). This inhibition was intensified when the cells were pretreated for 24 h with 200 nM Bryo1. Bryo1, Dol10 and Dol15 induced apoptosis which was seen on morphological examination, by flow cytometry and DNA fragmentation on agarose gel electrophoresis. Cells pretreated with Bryo1 and then exposed to Dol10 showed an increase in apoptosis compared with cells that were treated with the Dol10, Dol15 alone. Immunocytochemistry revealed that WSU-DLCL2 cells express the bcl-2 oncoprotein constitutively. bcl-2 expression was decreased when cells were treated with Bryo1, Dol10 or Dol15 and abolished with the Bryo1/Dol10 combination. WSU-DLCL2 cells were negative for p53 protein expression, upon treatment with Bryo1 or Dol10, the expression of p53 was weak and moderate with the Bryo1/Dol10 combination. The inverse correlation between bcl-2 and p53 oncoprotein expression seems to be related to induction of apoptosis in this lymphoma cell line.

Original languageEnglish (US)
Pages (from-to)392-397
Number of pages6
JournalAnti-Cancer Drugs
Volume6
Issue number3
StatePublished - 1995
Externally publishedYes

Fingerprint

dolastatin 10
Tumor Suppressor Protein p53
Lymphoma, Large B-Cell, Diffuse
Apoptosis
bryostatin 1
Cell Line
Agar Gel Electrophoresis
Oncogene Proteins
DNA Fragmentation

Keywords

  • B cell
  • bcl-2
  • bryostatin 1
  • diffuse large cell lymphoma
  • dolastatin 10
  • dolastatin 15
  • p53

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

Maki, A., Diwakaran, H., Redman, B., Al-Asfar, S., Pettit, G., Mohammed, R. M., & Al-Katib, A. (1995). The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. Anti-Cancer Drugs, 6(3), 392-397.

The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. / Maki, A.; Diwakaran, H.; Redman, B.; Al-Asfar, S.; Pettit, George; Mohammed, R. M.; Al-Katib, A.

In: Anti-Cancer Drugs, Vol. 6, No. 3, 1995, p. 392-397.

Research output: Contribution to journalArticle

Maki, A, Diwakaran, H, Redman, B, Al-Asfar, S, Pettit, G, Mohammed, RM & Al-Katib, A 1995, 'The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma', Anti-Cancer Drugs, vol. 6, no. 3, pp. 392-397.
Maki, A. ; Diwakaran, H. ; Redman, B. ; Al-Asfar, S. ; Pettit, George ; Mohammed, R. M. ; Al-Katib, A. / The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. In: Anti-Cancer Drugs. 1995 ; Vol. 6, No. 3. pp. 392-397.
@article{84f54e6c481346c2ab6174eb27bd611f,
title = "The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma",
abstract = "The effects of dolastatin 10 (Dol10) and dolastatin 15 (Dol15) alone, and after treatment with bryostatin 1 (Bryo1), on human diffuse large cell lymphoma cell line (WSU-DLCL2) were studied. At a concentration of 1.0 ng/ml Dol10 and Dol15 showed significant growth inhibition (p < 0.05). This inhibition was intensified when the cells were pretreated for 24 h with 200 nM Bryo1. Bryo1, Dol10 and Dol15 induced apoptosis which was seen on morphological examination, by flow cytometry and DNA fragmentation on agarose gel electrophoresis. Cells pretreated with Bryo1 and then exposed to Dol10 showed an increase in apoptosis compared with cells that were treated with the Dol10, Dol15 alone. Immunocytochemistry revealed that WSU-DLCL2 cells express the bcl-2 oncoprotein constitutively. bcl-2 expression was decreased when cells were treated with Bryo1, Dol10 or Dol15 and abolished with the Bryo1/Dol10 combination. WSU-DLCL2 cells were negative for p53 protein expression, upon treatment with Bryo1 or Dol10, the expression of p53 was weak and moderate with the Bryo1/Dol10 combination. The inverse correlation between bcl-2 and p53 oncoprotein expression seems to be related to induction of apoptosis in this lymphoma cell line.",
keywords = "B cell, bcl-2, bryostatin 1, diffuse large cell lymphoma, dolastatin 10, dolastatin 15, p53",
author = "A. Maki and H. Diwakaran and B. Redman and S. Al-Asfar and George Pettit and Mohammed, {R. M.} and A. Al-Katib",
year = "1995",
language = "English (US)",
volume = "6",
pages = "392--397",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma

AU - Maki, A.

AU - Diwakaran, H.

AU - Redman, B.

AU - Al-Asfar, S.

AU - Pettit, George

AU - Mohammed, R. M.

AU - Al-Katib, A.

PY - 1995

Y1 - 1995

N2 - The effects of dolastatin 10 (Dol10) and dolastatin 15 (Dol15) alone, and after treatment with bryostatin 1 (Bryo1), on human diffuse large cell lymphoma cell line (WSU-DLCL2) were studied. At a concentration of 1.0 ng/ml Dol10 and Dol15 showed significant growth inhibition (p < 0.05). This inhibition was intensified when the cells were pretreated for 24 h with 200 nM Bryo1. Bryo1, Dol10 and Dol15 induced apoptosis which was seen on morphological examination, by flow cytometry and DNA fragmentation on agarose gel electrophoresis. Cells pretreated with Bryo1 and then exposed to Dol10 showed an increase in apoptosis compared with cells that were treated with the Dol10, Dol15 alone. Immunocytochemistry revealed that WSU-DLCL2 cells express the bcl-2 oncoprotein constitutively. bcl-2 expression was decreased when cells were treated with Bryo1, Dol10 or Dol15 and abolished with the Bryo1/Dol10 combination. WSU-DLCL2 cells were negative for p53 protein expression, upon treatment with Bryo1 or Dol10, the expression of p53 was weak and moderate with the Bryo1/Dol10 combination. The inverse correlation between bcl-2 and p53 oncoprotein expression seems to be related to induction of apoptosis in this lymphoma cell line.

AB - The effects of dolastatin 10 (Dol10) and dolastatin 15 (Dol15) alone, and after treatment with bryostatin 1 (Bryo1), on human diffuse large cell lymphoma cell line (WSU-DLCL2) were studied. At a concentration of 1.0 ng/ml Dol10 and Dol15 showed significant growth inhibition (p < 0.05). This inhibition was intensified when the cells were pretreated for 24 h with 200 nM Bryo1. Bryo1, Dol10 and Dol15 induced apoptosis which was seen on morphological examination, by flow cytometry and DNA fragmentation on agarose gel electrophoresis. Cells pretreated with Bryo1 and then exposed to Dol10 showed an increase in apoptosis compared with cells that were treated with the Dol10, Dol15 alone. Immunocytochemistry revealed that WSU-DLCL2 cells express the bcl-2 oncoprotein constitutively. bcl-2 expression was decreased when cells were treated with Bryo1, Dol10 or Dol15 and abolished with the Bryo1/Dol10 combination. WSU-DLCL2 cells were negative for p53 protein expression, upon treatment with Bryo1 or Dol10, the expression of p53 was weak and moderate with the Bryo1/Dol10 combination. The inverse correlation between bcl-2 and p53 oncoprotein expression seems to be related to induction of apoptosis in this lymphoma cell line.

KW - B cell

KW - bcl-2

KW - bryostatin 1

KW - diffuse large cell lymphoma

KW - dolastatin 10

KW - dolastatin 15

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=0029019183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029019183&partnerID=8YFLogxK

M3 - Article

C2 - 7670136

AN - SCOPUS:0029019183

VL - 6

SP - 392

EP - 397

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 3

ER -